Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2019-03-08 Regulatory Filings
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings
2019-03-08 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce unscheduled material events or corporate changes. The text indicates it is a short filing (2597 characters) reporting the issuance of a press release attached as Exhibit 99.1. There is no substantive financial data or detailed report content within the text itself, only a reference to the press release. According to the 'Menu vs Meal' rule, such a brief filing that announces or attaches a press release without containing the full report or detailed financial data should be classified as a Regulatory Filing (RNS).
2019-03-06 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it includes a press release attached as Exhibit 99.1 but does not contain detailed financial statements or comprehensive financial data. The length is only 2597 characters, which is short and typical for an 8-K filing. There is no indication that this is an annual report, earnings release, or other detailed financial report. Therefore, this is a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories.
2019-03-06 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 6, 2019, by Galectin Therapeutics Inc. It announces the issuance of a press release regarding the company's results of operations and financial condition for the year ended December 31, 2018. The document states that the press release is attached as Exhibit 99.1 and that the information is being furnished, not filed, pursuant to Item 2.02 of Form 8-K. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release for the financial results. The length of the document is 4340 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document that announces or furnishes financial results without containing the full report or detailed financial data should be classified as an Earnings Release (ER). The document is not a full Annual Report (10-K), Interim Report (IR), or Management Discussion and Analysis (MDA). It is also not a Regulatory Filing (RNS) since it is a standard Form 8-K announcing earnings results. Therefore, the appropriate classification is Earnings Release (ER).
2019-03-06 English
FORM S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities offerings under the Securities Act of 1933. It includes detailed information about a rights offering, including the terms of the offering, use of proceeds, risk factors, and other disclosures typical of a registration statement. This is not a financial report, earnings release, or management discussion, but a capital raising filing. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement text, not just an announcement or a link to a report, so it is not an RPA or RNS. Hence, the correct classification is CAP with high confidence.
2019-03-06 English
FORM 10-K
Annual Report FY 2018
2019-03-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.